The purpose of this review is to summarize the current literature on continuous glucose monitors, focusing on devices that have been approved or are pending approval in the United States.
Introduction
The Diabetes Control and Complications Trial (DCCT) demonstrated that better glycemic control reduced the incidence of the microvascular complications associated with diabetes. The incidence of severe hypoglycemia, however, was three times higher in the intensively treated group than in the control group [1] . This risk of hypoglycemia makes it difficult to apply the findings of the DCCT to the general diabetic population. The frequency of home glucose monitoring (HGM) is one of the most significant factors in improving glycemic control. Yet despite performing seven blood glucose measurements each day, many severe hyper and hypoglycemic episodes are missed [2] . The hope for the future is that new innovations such as continuous glucose monitoring (CGM) will allow for improved glycemic control while minimizing the risk of severe hypoglycemia. This review addresses the evaluation of the performance of near continuous glucose sensors, the use of currently FDA approved CGM devices, and future use of CGM devices providing results in real time.
Continuous glucose sensors reviewed
(1) The Minimed-Medtronic Continuous Glucose Monitoring System (CGMS). This FDA-approved system uses a glucose-oxidase based needle-like subcutaneous sensor, which is connected via a cable to a monitor about the size of a pager that can be clipped onto a belt. Calibration values are obtained at least four times a day using the subject's home glucose meter. After being worn for about 3 days, the data stored in the monitor is downloaded in a physician's office and calibrated retrospectively. There is no real-time display of glucose values and no real-time alarms. The system measures glucose in a range of 40-400 mg/dl. In 2002 the sensor and software were modified and this is now called the CGMS 'Gold' system. (2) Minimed Guardian. This FDA-approved (but not yet marketed) device uses the same glucose-oxidase based needle sensor as the CGMS Gold, but a short cable connects the sensor to a small waterproof disk that can store and transmit the data wirelessly to a monitor that can be worn on a belt (like a beeper).
The Guardian 1 was developed to provide alarms for hyper and hypoglycemia, in real time, but does not display glucose values. The device can be downloaded retrospectively to review the glucose trends. The Guardian RT, a device currently pending FDA approval, would display glucose values in real time and also have alarms for hyper and hyperglycemia. The sensor and data storage and transmitting disk have also been integrated with the Medtronic Minimed 722 insulin infusion pump. This integrated system allows for results from the continuous glucose sensor to be directly transmitted and displayed on the pump screen. (3) Cygnus GlucoWatch (GW2) Biographer. This FDAapproved non-invasive device is worn like a watch with a disposable sensor. The GW2 uses reverse iontophoresis to obtain an interstitial glucose value every 10 minutes for up to 13 hours following a 2-hour initialization period. In addition to the real-time glucose values, the watch has alarms for hyperglycemia, hypoglycemia, and an alarm for pending hypoglycemia.
Results have a 17-18-minute lag when compared with blood glucose levels. (4) TheraSense Navigator by Abbott Diabetes Care. This device uses a needle-like subcutaneous glucose oxidase based sensor with an osmium-based mediator molecule that decreases the sensor's oxygen dependency. The sensor is inserted under the skin and then a data processing and transmitting device is directly connected to the sensor. Data is transmitted wirelessly from the sensor to a receiver with an integrated blood-glucose meter that can be worn on the belt like a beeper. The sensor and transmitter unit that is attached to the subject is waterproof. Glucose is measured over a range of 20-500 mg/dl with results updated in the display every 10 minutes. There are programmable alarms for pending hyper and hypoglycemia. (5) Dexcom implanted sensor. The sensor is a small, cylindrical device that is implanted in the subcutaneous tissue of the abdomen by a surgeon. After several weeks of vascularization the sensor will transmit glucose data every 5 minutes.
Assessing performance of continuous glucose monitoring devices
Developing methods to assess the performance of CGM is an area of ongoing development. Clearly, our traditional methods of point-to-point comparisons used in assessing meter accuracy will not be adequate to assess the accuracy of continuous glucose sensors. We will need to develop new standards that reflect the potential clinical utility of continuous glucose data. The accuracy of features such as real-time alerts of impending hyper or hypoglycemic events and real-time alarms for glucose values outside the appropriate range will need to be studied. Continuous glucose monitors typically measure glucose levels every 5-10 minutes providing 144-288 measurements a day. This high frequency of glucose measurements allows for the assessment of short-term glycemic trends and offers the potential to predict glucose levels into the future. One way to highlight the difference between home glucose meters and continuous glucose sensors is to compare a high resolution photograph, analogous to single home glucose meter reading, with a lower resolution video recording, analogous to continuous glucose monitoring. While the video has lower resolution in each frame, its multiple frames capture the sequence of events over time.
In the evaluation of home glucose meters, we have traditionally used a point-to-point comparison, comparing a home glucose meter result to a reference value obtained using a laboratory-based assay. a. In the hypoglycemic range, a fixed absolute error will be given greater weight (e.g., an error of 15 mg/dl at 300 mg/dl results in a MARD of 5%), while at a reference glucose of 50 mg/dl this is a MARD of 30%. b. A few outliers may cause a significant increase in the mean RAD, therefore the median RAD may be the preferred assessment.
(3) The accuracy of a sensor must be determined using independent reference glucose values. When glucose values used to calibrate the device are also used to assess sensor accuracy [3, 4] , this is more an evaluation of the performance of the calibration equation and not an independent measure of sensor accuracy. (4) Studies to assess sensor function should include a broad range of reference glucose values so sensor function can be assessed in the hypoglycemic, euglycemic, and hypergly cemic ranges [5] . Additionally, sensor function must be assessed during the nighttime as well as the daytime. Sensors can be worn for a number of days, and sensor function must be assessed across the entire duration of sensor wear.
The Diabetes Research in Children Network (DirecNet) is a multicenter National Institutes of Health-funded collaborative study group. A major objective of DirecNet is to critically evaluate the clinical usefulness of current and future continuous glucose sensors in youth with type 1 diabetes. One of their first goals was to assess the accuracy of the two approved continuous glucose sensors in the United States, the Minimed CGMS and the Cygnus GlucoWatch. In a series of papers they have published definitive accuracy studies on these devices [6-10] (http://public.direc.net/). A summary of their results and the results of several other point-to-point accuracy studies is presented in Table 1 . In these studies, the DirecNet group assessed the accuracy of both the CGMS and GWB in the hypoglycemic, euglycemic, and hyperglycemic ranges, and found that both sensors were less accurate during hypoglycemia. There was no effect of gender, ethnicity, body mass index, or subject age (from 3-18 years old) on the function of either sensor. CGMS sensors were equally accurate on the first, second, and third days of wear, while the GlucoWatch was slightly less accurate during the last 5 hours of wear. The Gluco-Watch showed no change in accuracy when comparing daytime to nighttime function, while the Minimed CGMS was less accurate at night with a bias to read lower at night.
All point-to-point glucose comparisons have the significant disadvantage that they ignore the ability of the CGM to assess glucose trends. The continuous glucoseerror grid analysis (CG-EGA) was developed to incorporate trend analysis when assessing sensor function [11 • ]. The CG-EGA combines point-error grid analysis and a rate-error gird analysis, which assesses the sensor's ability to capture the direction and rate of blood glucose change. The CG-EGA also proposes a separate evaluation of CGM accuracy for each of three blood glucose ranges: hypoglycemic (#70 mg/dl), euglycemic (70-180 mg/dl), and hyperglycemic ($180 mg/dl). Again, there are zones that define when an error would be clinically acceptable (A&B), or would result in inappropriate clinical decisions. The CG-EGA analysis is a reasonable first step in asses-sing how well a sensor will function in real time when it is used to make insulin dose decisions. There is only one report using the CG-EGA to assess a CGM, the TheraSense Navigator [11 • ]. The percentage of Navigator readings that were clinically accurate or resulted in benign errors was 73.5% during hypoglycemia, 99% during euglycemia, and 95.4% during hyperglycemia.
From a patient perspective, one of the critical functions of a real-time continuous glucose sensor is the ability to detect clinically significant events, both hyperglycemic and hypoglycemic. Avoidance of nocturnal hypoglycemic seizures is particularly important. The DirecNet study group has therefore evaluated hypoglycemic alarms using an event-based analysis allowing the sensor 30 minutes to recognize hypoglycemia [10] . When using event-based analysis, it is important to decide how much time the sensor has to recognize the event. Many current continuous glucose monitoring devices measure interstitial glucose and there is a physiologic lag time between the blood glucose and the interstitial glucose (estimated between 3 and 14 minutes [12, 13] ). An important factor in an eventbased analysis is how long the event can be tolerated before it becomes clinically significant for the patient. Individuals vary in how long they can tolerate hypoglycemia before having a seizure based on their age, their past history of hypoglycemic seizures, and whether they have a preexisting seizure focus. It is of interest that in all the published studies of continuous glucose sensor use, no one has reported a case of a subject wearing a sensor and having a seizure, despite many prolonged episodes of hypoglycemia (Table 2) . We are only aware of one case where a person wearing a CGMS device experienced a seizure (personal communication Kevin Kaiserman, MD), and this occurred after 4 hours of nocturnal hypoglycemia (<40 mg/dl) on the retrospective CGMS tracing. It would appear from this body of data that if a sensor detected hypoglycemia within 30 minutes, most individuals would not have a seizure. The DirecNet study group performed event-based analysis using data from the GlucoWatch, the first, and currently only, approved real-time sensor [10] . The GlucoWatch has an alarm that sounds when either the measured glucose drops below the level set by the user (the 'hypoglycemic alarm') or the trend of glucose values projects the glucose will reach the hypoglycemic threshold within 20 minutes (the 'down alert' alarm). With the hypoglycemic alarm set to 60 mg/dl, there was a hypoglycemic alarm for 23% of the true hypoglycemic events and 16% of the hypoglycemic alarms were falsely positive. When the down alert alarm was also used to detect hypoglycemia, the GlucoWatch alarmed for 77% of the true nocturnal hypoglycemic events, but the incidence of false positive alarms increased to 62%. Using the trend analysis, 'down alert' significantly improved detection of hypoglycemic alarms, and if treatment had been given at the time of the first alarm, many hypoglycemic events would have been avoided. It remains to be determined if prospective treatment of pending hypoglycemia will result in an increase in HbA1c levels.
Retrospective use of continuous glucose monitoring system
Retrospective use of the CGMS has allowed recognition of glucose patterns that were otherwise missed by usual home glucose monitoring [14,15 • ,16,17 • ,18-20] . The most common patterns observed have been postprandial hyperglycemia, especially after breakfast, nocturnal hypoglycemia, and over-treatment of hypoglycemic reactions. Observing these patterns has resulted in changes in the basal insulin requirements (85% of patients), changes in meal carbohydrate to insulin ratios (70% of patients), changes in the management of hypoglycemia (55% of patients), and changes in correction algorithms (30% of patients) [18] . CGMS has also been useful in recognizing the 'dawn' phenomenon (37% of patients) and Somogyi reactions (63% of patients) [16] .
A number of studies have attempted to determine if a retrospective review of glucose values would improve glycemic control ( Table 3) . Most of these studies have shown minimal, if any, effect of CGMS use on improving HbA1c levels. All of these studies, however, have been hampered by the infrequent use of the CGMS over the study's duration (4%-20% of study days). A more appropriate study would be to use the CGMS 5-6 days/wk throughout the study duration with frequent CGMS downloads every 2-3 days for assessment of glucose patterns.
Another potential benefit from using the CGMS is detection of unrecognized hypoglycemia, one of the most common findings in analysis of CGMS data (Table 2 ). In assessing retrospective use of the CGMS to prevent hypoglycemia, however, there is only one study demonstrating a benefit. In this study, there was an equal frequency of hypoglycemic episodes in the group, which was allowed to see their CGMS results compared with the group blinded to their CGMS results, but the duration of the hypoglycemic episodes in the unblinded group was shorter (49 minutes compared with 81 minutes) [15 • ]. Until there is a large, randomized, long-term study, we cannot know if using glucose sensors will reduce the incidence of severe hypoglycemic episodes resulting in seizures or loss of consciousness.
Real-time use of continuous glucose sensors
The first real-time glucose sensor approved by the FDA was the GlucoWatch by Cygnus. One of the major reasons patients and their parents were interested in using this device was the alarm function to warn of potential, severe nocturnal hypoglycemia. Nineteen subjects who participated in the DirecNet GlucoWatch accuracy study were therefore videotaped overnight to determine if the alarms were effective in awakening children when they were hypoglycemic. In all 11 instances when a child had a reference glucose below 70 mg/dl they were awoken by a GlucoWatch alarm [21] . In contrast, when children were hyperglycemic (>300 mg/dl) they only awoke on 2 of 13 occasions. It is encouraging that children were able to respond to an alarm while they were sleeping and hypoglycemic. We postulate that the release of catecholamines in response to their hypoglycemia may have resulted in a lighter state of sleep and a lower arousal threshold.
Use of a real-time sensor may also result in improved glycemic control. The DirecNet study group therefore randomized 200 children into a 6-month trial in which half the children were randomized to use the GlucoWatch while half served as a control group. Both groups had equal contact with study investigators. There was no improvement in A1c levels nor any reduction in the incidence of hypoglycemia in the group using the GlucoWatch compared with the control group [22] . Although subjects were encouraged to use the GlucoWatch frequently, there was a significant decline in GWB use during the study. Reasons given for declining use included skin irritation (76%), skips too frequently (56%), alarms too frequently (47%), and does not provide accurate readings (33%). The GlucoWatch has also been found to function poorly during exercise [23] .
The Minimed Guardian I system (recently approved by the FDA, but not yet marketed) utilizes the Minimed subcutaneous glucose sensor, a real-time algorithm, and provides the subject with alarms for hypoglycemic and hyperglycemic events. It does not, however, provide the wearer with glucose values in real time. In an initial study, 71 subjects were randomized to use this system with the alarms disabled (n = 35) or with the alarm system activated (n = 36) [24 • ]. Both groups initially wore the sensor blinded for the first 6 days of the study and then the alarm system was activated for the 'Alert' group while the control group remained blinded to the alarms for an additional 6 days of sensor wear. The hypoglycemia alert was set to 70 mg/dl and had a 67% sensitivity (true positive) while 47% of alarms were false positive (Table 4 ). The hypergly-cemic alarm was set to 250 mg/dl and had 63% sensitivity (true positives) and 19% were false alarms. This study was too short to see any effect on HbA1c levels.
TheraSense has developed a subcutaneous, needle-like glucose sensor, the Navigator. Results are displayed in real time with arrows to indicate the rate of glucose change and alarms can be set for hypoglycemia, hyperglycemia, and projected low and high glucose values. Initial accuracy data compared 12,677 reference values to Navigator glucose values (after excluding calibration values) [25] . In this analysis 98.3% of values were in the A&B zones of the Clark error grid and the mean RAD was 17%, comparable to the Minimed Gold CGMS ( Dexcom has developed an implantable subcutaneous continuous glucose monitoring system. This device is surgically implanted in the subcutaneous tissue as an outpatient procedure. After the bio-interface vascularizes and stabilizes, the sensor can provide glucose results in real time. Fifteen adults used this device with a real-time display of glucose values for an average of 44 days with alarm set points at 55 mg/dl and 200 mg/dl. In the one published paper on this device [26 • ], accuracy in real time and the true positive and false positive alarm rates are not given. Subjects initially wore the device for an average of 50 days blinded to their glucose results, and subsequently the results of glucose values were displayed to the subjects in real time for an average of 44 days. When the subject were able to see their results in real time they spent 47% less time below 55 mg/dl and 25% less time above 200 mg/dl compared with the time when they were blinded to the sensor glucose values. With longer-term use, it remains to be determined whether these results will achieve lower HbA1c levels and a lower incidence of severe hypoglycemic reactions.
The future
Multiple companies and investigators are developing new devices or devices with improved accuracy for subcutaneous monitoring. FDA guidelines on how to assess the function of new sensors are needed, and studies of these sensors will need to demonstrate clinical efficacy before they will be widely used. One of the keys to the success of CGM devices will also be patient and physician acceptance. Devices will need to be reasonably comfortable to wear and provide the patient with a measurable improvement in their day-to-day management. A decrease in the risk of nocturnal hypoglycemia without an undue number of false alarms will be an initial goal. Patients and health care professionals will need to learn how to make diabetes management decisions not only based on current glucose levels, but also use information about the rate of change of glucose values and incorporate predicted glucose levels into management decisions. Patients will need to be willing to treat predicted hypoglycemia before it occurs and be given guidelines for insulin adjustments that take into account their glucose trends. Only randomized controlled studies with near continuous use of real-time glucose sensors will be able to determine if this results in over treatment and a resultant increase in HbA1c levels.
An initial closed loop insulin delivery system could be used to control nocturnal glucose levels. Preliminary studies from Dr Gary Steil at Medtronic Minimed have demonstrated the feasibility of using current sensor technology to achieve glucose control overnight without hypoglycemia [27] . A partial closed loop with bolus injections to cover meals based on the carbohydrate content of the meal with closed loop control of nocturnal glucose levels may be the next step before a completely closed loop system is initiated.
Uses outside of diabetes
Continuous glucose monitors may play an increased role in diseases other than diabetes. The CGMS has also been used to monitor children with other diseases associated with hypoglycemia, such as hyperinsulinism [28] and glycogen storage disease [29] , and conditions associated with hyperglycemia such as pregnancy [30, 31] and cystic fibrosis [31] . One of the most promising uses for CGM may be in the intensive care unit. Tight glycemic control in the intensive care unit has produced dramatic improvements in morbidity and mortality [32] and the CGMS has been successfully used in the intensive care unit setting [33 • ]. When intravenous glucose infusions are provided at a steady rate, the blood glucose fluctuations associated with oral absorption of meals is avoided. In an intensive care unit setting insulin is delivered intravenously, which significantly improves the pharmacodynamics of insulin delivery in a closed loop system. The intensive care unit may therefore be one of the initial settings where closed loop delivery of insulin using a continuous glucose sensor will be implemented.
Conclusion
Continuous glucose monitoring systems are currently less accurate, using point-to-point comparisons, than home glucose meters. In the future, continuous glucose sensors will likely become more widely used as successive generations will result in improvements in their accuracy, their ease of use, and become more comfortable to wear. The next generation of sensors will provide data in real time with trend analysis and alarms for pending hyper and hypoglycemia. These sensors will be designed for near-continuous use at home by patients. Both patients and physicians will need to learn how to best use the realtime data and pending hypo and hyperglycemic alarms to make treatment decisions. It will be important to determine if near-continuous use of sensors over extended periods of time will result in significant improvements in A1c levels, a decrease in the incidence of hypoglycemia, and an improvement in the quality of life for people with diabetes. In the future, sensors will directly control insulin infusion pumps, greatly easing the management challenges of diabetes. Expanded use of continuous glucose sensors will be useful in managing type 1, type 2, and gestational diabetes. The use of this technology may also be useful in monitoring glucose levels in hospitalized patients both with and without diabetes following surgery or in an intensive care unit.
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